SentenceNon-cash royalty revenue related to our agreement with GSK increased $7.6 million, to approximately $108.6 million for the year ended December 31, 2025, from $101.0 million for the year ended December 31, 2024, due to increased net sales of GSK's vaccines containing our QS-21 STIMULON adjuvant.

AGEN 10-Kaccession 0001193125-26-108632filed Mar 16 '26AGEN

ALECAlector, Inc.

SentenceOur portfolio includes nivisnebart (formerly AL101/GSK4527226), an investigational PGRN-elevating antibody that has completed enrollment in a placebo-controlled, double-blinded Phase 2 study in early Alzheimer's disease under our July 2021 Collaboration and License Agreement (GSK Agreement) with Glaxo Wellcome UK Limited, a subsidiary of GlaxoSmithKline plc (GSK).

ALEC 10-Kaccession 0001193125-26-071593filed Feb 25 '26ALEC

ANABAnaptysbio, Inc

SentenceWe currently recognize revenue from milestones and royalties achieved under our immuno-oncology collaboration with GSK and license and transition services revenue from our collaboration with Vanda.

ANAB 10-Kaccession 0001193125-26-088290filed Mar 3 '26ANAB

CAMPCamp4 Therapeutics Corp

SentenceUnder the terms of this agreement, we granted GSK an exclusive, worldwide license under certain patents and know-how to research, develop, manufacture and commercialize certain compounds and products directed to the Collaboration Targets.

CAMP 10-Kaccession 0001736730-26-000016filed Mar 5 '26CAMP

CDXSCodexis, Inc.

SentenceTo date, we have entered into platform technology licensing agreements with each of GlaxoSmithKline Intellectual Property Development Limited, a subsidiary of GlaxoSmithKline plc ("GSK"), Merck & Co., Inc. ("Merck & Co") and Novartis Pharma AG ("Novartis").

CDXS 10-Kaccession 0001200375-26-000006filed Mar 11 '26CDXS

GPKGraphic Packaging Holding Co

SentenceHealth/beauty customers include GlaxoSmithKline, Bayer, Johnson & Johnson, Abbott, Novartis, L'Oréal S.A., Procter & Gamble and Colgate-Palmolive.

GPK 10-Kaccession 0001408075-26-000009filed Mar 2 '26GPK

INVAInnoviva, Inc.

SentenceCurrently, we derive the majority of our revenues from GSK and our near-term success depends in large part on GSK's ability to successfully develop and commercialize the products in the respiratory programs partnered with GSK.

INVA 10-Kaccession 0001193125-26-071776filed Feb 25 '26INVA

IONSIonis Pharmaceuticals Inc

SentenceFor example, in the past we have manufactured clinical trial material for AstraZeneca, Biogen, GSK, Roche, and Novartis and commercial drug supply for Biogen.

IONS 10-Kaccession 0000874015-26-000115filed Feb 26 '26IONS

SPROSpero Therapeutics, Inc.

SentenceIn addition to the milestones described above, GSK is obligated to pay royalties to us on annual net sales of GSK Licensed Products in the GSK Territory. Such royalties are 1% for annual sales up to $750.0 million each year and range from high single-digit percentages on annual net sales above $750.0 million each year to low double-digit percentages on annual net sales above $1,000.0 million each year.

SPRO 10-Kaccession 0001193125-26-126192filed Mar 26 '26SPRO

TBPHTheravance Biopharma, Inc.

SentenceWe received the $225.0 million from GSK in June 2025.

TBPH 10-Kaccession 0001104659-26-033077filed Mar 23 '26TBPH

TEMTempus AI, Inc.

SentenceUnder the GSK Agreement, we agreed, on a non-exclusive basis, to provide GSK with certain of our products and services, including licensed data, sequencing, clinical trial matching, organoid modeling services, algorithm development, and others.

TEM 10-Kaccession 0000950170-25-025603filed Feb 24 '25TEM

WVEWave Life Sciences Ltd.

SentenceRevenue for the year ended December 31, 2025 was $42.7 million, and was earned under the GSK Collaboration Agreement.

WVE 10-Kaccession 0001193125-26-073472filed Feb 26 '26WVE

customer

CHRSCoherus Oncology, Inc.

SentenceIn December 2020, Surface entered into the GSK Agreement. Pursuant to the GSK Agreement, Surface granted GSK a worldwide exclusive, sublicensable license to develop, manufacture and commercialize antibodies that target PVRIG, including the antibody GSK4381562 (the "Licensed Antibodies").

CHRS 10-Kaccession 0001104659-26-025308filed Mar 9 '26CHRS

INVAInnoviva, Inc.

SentencePursuant to the GSK Agreements, GSK is responsible for the development and commercialization of products in the partnered respiratory programs.

Order: filed share, then A–Z, unlisted last

Methodology

ties · implied moves · holdersMethod

Ties Implied moves Holders

Dependency

Sources

Methodology

ties · implied moves · holdersMethod

Ties Implied moves Holders